


## Fasitibant chloride hydrochloride

Cat. No.:	HY-106277A
CAS No.:	869880-33-1
Molecular Formula:	C <sub>36</sub> H <sub>50</sub> Cl <sub>4</sub> N <sub>6</sub> O <sub>6</sub> S
Molecular Weight:	836.7
Target:	Bradykinin Receptor
Pathway:	GPCR/G Protein
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.



### BIOLOGICAL ACTIVITY

<b>Description</b>	Fasitibant chloride hydrochloride (MEN16132) is a potent, selective, high affinity, and long-lasting nonpeptide bradykinin B <sub>2</sub> (BK <sub>2</sub> ) receptor antagonist. Fasitibant chloride hydrochloride has proinflammatory effects and can be used for the research of osteoarthritis and rheumatoid arthritis <sup>[1]</sup> .								
<b>IC<sub>50</sub> &amp; Target</b>	Bradykinin B2 Receptor (B2R)								
<b>In Vitro</b>	Fasitibant chloride hydrochloride (1 μM; 30 min) reduces BK induced PGE <sub>2</sub> formation and COX-2 gene expression in synovial cells <sup>[1]</sup> . MCE has not independently confirmed the accuracy of these methods. They are for reference only.								
<b>In Vivo</b>	Fasitibant chloride hydrochloride (100 μg; knee injection; single dose) significantly reduces the release of IL-1b, IL-6, GRO/PINC-1 synovial cytokines, the formation of PGE metabolites, the activity of myeloperoxidase (MPO) induced by Carrageenan (HY-125474) in rats, and the effect was more significant when combined with Dexamethasone (HY-14648) <sup>[2]</sup> . MCE has not independently confirmed the accuracy of these methods. They are for reference only.								
	<table border="1"> <tr> <td>Animal Model:</td> <td>Male wistar rats with inflammatory arthritis<sup>[2]</sup></td> </tr> <tr> <td>Dosage:</td> <td>100 μg per knee</td> </tr> <tr> <td>Administration:</td> <td>Injection into the knee joint; 100 μg per knee; combines with dexamethasone</td> </tr> <tr> <td>Result:</td> <td>Was more effective than each drug administered alone in inhibiting knee joint inflammation. Reduced joint pain and diminished joint oedema.</td> </tr> </table>	Animal Model:	Male wistar rats with inflammatory arthritis <sup>[2]</sup>	Dosage:	100 μg per knee	Administration:	Injection into the knee joint; 100 μg per knee; combines with dexamethasone	Result:	Was more effective than each drug administered alone in inhibiting knee joint inflammation. Reduced joint pain and diminished joint oedema.
Animal Model:	Male wistar rats with inflammatory arthritis <sup>[2]</sup>								
Dosage:	100 μg per knee								
Administration:	Injection into the knee joint; 100 μg per knee; combines with dexamethasone								
Result:	Was more effective than each drug administered alone in inhibiting knee joint inflammation. Reduced joint pain and diminished joint oedema.								
	<table border="1"> <tr> <td>Animal Model:</td> <td>Male Wistar rats with inflammatory arthritis<sup>[2]</sup></td> </tr> <tr> <td>Dosage:</td> <td>100 μg per knee</td> </tr> <tr> <td>Administration:</td> <td>Injection into the knee joint; 100 μg per knee; combines with dexamethasone</td> </tr> <tr> <td>Result:</td> <td>Was more effective than each drug administered alone in inhibiting knee joint inflammation.</td> </tr> </table>	Animal Model:	Male Wistar rats with inflammatory arthritis <sup>[2]</sup>	Dosage:	100 μg per knee	Administration:	Injection into the knee joint; 100 μg per knee; combines with dexamethasone	Result:	Was more effective than each drug administered alone in inhibiting knee joint inflammation.
Animal Model:	Male Wistar rats with inflammatory arthritis <sup>[2]</sup>								
Dosage:	100 μg per knee								
Administration:	Injection into the knee joint; 100 μg per knee; combines with dexamethasone								
Result:	Was more effective than each drug administered alone in inhibiting knee joint inflammation.								

---

Reduced joint pain and diminished joint oedema.

---

## REFERENCES

---

[1]. S Meini, et al. Fasitibant prevents the bradykinin and interleukin 1 $\beta$  synergism on prostaglandin E<sub>2</sub> release and cyclooxygenase 2 expression in human fibroblast-like synoviocytes. *Naunyn Schmiedebergs Arch Pharmacol.* 2012 Aug;385(8):777-86.

[2]. Claudio Valenti, et al. Fasitibant chloride, a kinin B<sub>2</sub> receptor antagonist, and dexamethasone interact to inhibit carrageenan-induced inflammatory arthritis in rats. *Br J Pharmacol.* 2012 Jun;166(4):1403-10.

---

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: [tech@MedChemExpress.com](mailto:tech@MedChemExpress.com)

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA